Bausch + Lomb BLCO OTC — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch + Lomb in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bausch + Lomb's otc — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bausch + Lomb's OTC — total revenues?
- Bausch + Lomb (BLCO) reported OTC — total revenues of $444M in Q1 2026.
- How has Bausch + Lomb's OTC — total revenues changed year-over-year?
- Bausch + Lomb's OTC — total revenues increased by 8.6% year-over-year, from $409M to $444M.
- What is the long-term trend for Bausch + Lomb's OTC — total revenues?
- Over 4 years (2021 to 2025), Bausch + Lomb's OTC — total revenues has grown at a 7.1% compound annual growth rate (CAGR), from $1.39B to $1.84B.
- What does OTC — total revenues mean?
- This metric represents the total gross revenue generated from the sale of over-the-counter ophthalmic and vision care products. It reflects the market demand and commercial performance of consumer-facing eye health solutions that do not require a prescription. Tracking this revenue stream provides insight into the company's brand strength and competitive positioning within the retail consumer health market.